Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 19.69 is 41% above its 5-year average of 13.95, around the middle of its 5-year range (5.06–42.22).
As of the fiscal period ended Tuesday, June 30, 2026. 87.22% above its 12-month average of 10.52.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 19.69.
CURRENT RATIO
19.69
CURRENT RATIO AVG TTM
10.52
CURRENT RATIO AVG 3Y
9.84
CURRENT RATIO AVG 5Y
13.95
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+87.22%
CURRENT VS 3Y AVG
+100.04%
CURRENT VS 5Y AVG
+41.21%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.50
median of 716 covered companies
CURRENT VS SECTOR MEDIAN
+463.46%
vs the sector median at left
Faeth Therapeutics, Inc.
Market Cap
$752.35M
Current Ratio
19.69
TTM Avg
10.52
3Y Avg
9.84
5Y Avg
13.95
Market Cap
$764.79M
Current Ratio
18.86
TTM Avg
23.23
3Y Avg
26.78
5Y Avg
32.61
Market Cap
$746.62M
Current Ratio
16.09
TTM Avg
8.04
3Y Avg
7.87
5Y Avg
9.13
Market Cap
$778.76M
Current Ratio
9.39
TTM Avg
11.79
3Y Avg
11.79
5Y Avg
11.79
Market Cap
$738.63M
Current Ratio
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
Market Cap
$784.23M
Current Ratio
13.37
TTM Avg
5.16
3Y Avg
5.50
5Y Avg
4.90
Market Cap
$723.66M
Current Ratio
19.31
TTM Avg
14.05
3Y Avg
7.67
5Y Avg
5.91
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $752.35M | 19.69 | 10.52 | 9.84 | 13.95 |
| Design Therapeutics, Inc. (DSGN)vs › | $764.79M | 18.86 | 23.23 | 26.78 | 32.61 |
| Candel Therapeutics, Inc. (CADL)vs › | $746.62M | 16.09 | 8.04 | 7.87 | 9.13 |
| Mesa Laboratories, Inc. (MLAB)vs › | $778.67M | 2.07 | 1.18 | 1.89 | 3.24 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $778.76M | 9.39 | 11.79 | 11.79 | 11.79 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $738.63M | 0.95 | 4.92 | 2.98 | 5.72 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $784.23M | 13.37 | 5.16 | 5.50 | 4.90 |
| Geron Corporation (GERN)vs › | $789.07M | 6.92 | 5.11 | 3.93 | 4.38 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $723.66M | 19.31 | 14.05 | 7.67 | 5.91 |
| AdaptHealth Corp. (AHCO)vs › | $795.92M | 1.12 | 1.18 | 1.21 | 1.17 |
Current Ratio
19.69
Quick Ratio
19.69
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 19.69 |
| 2026-03-31 | 14.39 |
| 2025-12-31 | 5.06 |
| 2025-09-30 | 5.81 |
| 2025-06-30 | 7.64 |
| 2025-03-31 | 6.82 |
| 2024-12-31 | 7.70 |
| 2024-09-30 | 8.84 |
| 2024-06-30 | 10.90 |
| 2024-03-31 | 12.07 |
| 2023-12-31 | 11.92 |
| 2023-09-30 | 11.86 |
| 2023-06-30 | 15.13 |
| 2023-03-31 | 13.00 |
| 2022-12-31 | 11.98 |
| 2022-09-30 | 13.95 |
| 2022-06-30 | 23.46 |
| 2022-03-31 | 18.27 |
| 2021-12-31 | 30.38 |
| 2021-09-30 | 30.05 |
| 2021-06-30 | 42.22 |
| 2021-03-31 | 69.81 |
| 2020-12-31 | 4.16 |
| 2020-09-30 | 0.94 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.02 |
